共 48 条
[11]
Martel-Laferriere V(2014)Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis N Engl J Med 370 1879-713
[12]
Backus LI(2015)Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1 N Engl J Med 373 705-1603
[13]
Belperio PS(2014)Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin N Engl J Med 370 1594-1614
[14]
Shahoumian TA(2014)Retreatment of HCV with ABT-450/r–ombitasvir and dasabuvir with ribavirin N Engl J Med 370 1604-1231
[15]
Pawlotsky JM(2015)Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial JAMA 313 1223-1982
[16]
Leidner AJ(2014)ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis N Engl J Med 370 1973-1455
[17]
Chesson HW(2013)Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies Gastroenterology 144 1450-undefined
[18]
Xu F(2014)Safety and efficacy of ombitasvir—450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens J Int AIDS Soc 17 19500-undefined
[19]
Afdhal N(undefined)undefined undefined undefined undefined-undefined
[20]
Reddy KR(undefined)undefined undefined undefined undefined-undefined